XML 86 R75.htm IDEA: XBRL DOCUMENT v3.25.3
Segment, Geographic and Other Revenue Information - Schedule of Significant Biopharma Segment Expenses (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 28, 2025
Sep. 29, 2024
Sep. 28, 2025
Sep. 29, 2024
Segment Reporting Information [Line Items]        
Revenues: $ 16,654 $ 17,702 $ 45,022 $ 45,864
Cost of sales [1] 4,172 5,263 10,795 11,942
Selling, informational and administrative expenses [1] 3,186 3,244 9,632 10,456
Research and development expenses [1] 2,546 2,598 7,231 7,787
Acquired in-process research and development expenses 1,390 13 1,401 20
Other (income)/deductions––net 517 243 2,210 2,030
Income from continuing operations before provision/(benefit) for taxes on income [2] 3,334 4,715 9,162 8,033
Biopharma [Member]        
Segment Reporting Information [Line Items]        
Revenues: 16,310 17,392 44,056 44,987
Cost of sales 3,526 4,630 8,915 9,684
Selling, informational and administrative expenses 2,210 2,253 6,739 7,143
Research and development expenses 2,185 2,355 6,235 6,799
Acquired in-process research and development expenses 40 13 51 20
Other (income)/deductions––net (120) (128) (313) (365)
Income from continuing operations before provision/(benefit) for taxes on income $ 8,469 $ 8,269 $ 22,429 $ 21,707
[1] Exclusive of amortization of intangible assets.
[2] Income from continuing operations before provision/(benefit) for taxes on income. Effective in the third quarter of 2025, certain costs for corporate affairs, which were previously reported in the operating results of corporate enabling functions, are reported in the operating results of our Biopharma reportable segment. In connection with this reporting change, we reclassified costs of approximately $74 million in the first six months of 2025, $50 million in the third quarter of 2024 and $132 million in the first nine months of 2024 from Other business activities to Biopharma to conform to the current period presentation.